Zheng Quan Zhi Xing·2025-07-28 16:13Summary of Key Points Core Viewpoint The report outlines the process and results of a share transfer inquiry by Chengdu Yuandong Pharmaceutical Co., Ltd. to specific institutional investors, facilitated by CITIC Securities, ensuring compliance with relevant regulations and fairness in the transfer process [1][5][12]. Group 1: Overview of the Share Transfer - The share transfer involves three entities: Chengdu Nanyuan Investment Partnership, Chengdu Zhuyuan Investment Partnership, and Chengdu Juyuan Investment Partnership, collectively referred to as the "transferors" [1]. - The maximum number of shares proposed for transfer is 3,369,550 shares, representing 1.91% of the total share capital of the company [6][8]. - The transferors hold pre-IPO shares, with specific quantities and ownership percentages detailed for each entity [1][6]. Group 2: Pricing and Transfer Process - The minimum price for the share transfer was determined based on the transferors' financial needs and is not lower than the price set in the subscription invitation sent by CITIC Securities [2]. - The transfer price was finalized at 42.06 yuan per share, resulting in a total transaction amount of 141,723,273 yuan [6][8]. - The transfer process involved sending subscription invitations to 418 institutional investors, including various types of investment firms [5][6]. Group 3: Compliance and Verification - CITIC Securities conducted thorough checks on the qualifications of both the transferors and the transferees, ensuring compliance with the relevant regulations [10][11]. - The report confirms that all participating institutional investors met the necessary criteria and did not have any conflicts of interest with the transferors [12]. - The entire share transfer process adhered to the principles of fairness and compliance with applicable laws and regulations [12][13].